Reuters logo
Bayer seeks wider use for eye drug Eylea in Europe
November 7, 2013 / 11:16 AM / in 4 years

Bayer seeks wider use for eye drug Eylea in Europe

FRANKFURT, Nov 7 (Reuters) - German drugmaker Bayer said it filed for marketing approval in Europe for the use of eye drug Eylea as a treatment of diabetic macular oedema.

Bayer has said it expects Eylea, also known as VEGF Trap-Eye, to generate more than 1 billion euros ($1.35 billion) in peak annual sales.

The injection, which Bayer is co-developing with Regeneron , is already approved for other eye diseases.

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below